Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 2/20 | 0.52 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ERN1 | O75460 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | TTR | P02766 | 2/20 | 0.41 |
| ▸ | TUBB4A | P04350 | 4/20 | 0.41 |
| ▸ | TUBB | P07437 | 4/20 | 0.41 |
| ▸ | TUBA3C | P0DPH7 | 4/20 | 0.41 |
| ▸ | TUBA1B | P68363 | 4/20 | 0.41 |
| ▸ | TUBA4A | P68366 | 4/20 | 0.41 |
| ▸ | TUBB4B | P68371 | 4/20 | 0.41 |
| ▸ | TUBB3 | Q13509 | 4/20 | 0.41 |
| ▸ | TUBB2A | Q13885 | 4/20 | 0.41 |
| ▸ | TUBB8 | Q3ZCM7 | 4/20 | 0.41 |
| ▸ | TUBA3E | Q6PEY2 | 4/20 | 0.41 |
| ▸ | TUBA1A | Q71U36 | 4/20 | 0.41 |
| ▸ | TUBA1C | Q9BQE3 | 4/20 | 0.41 |
| ▸ | TUBB6 | Q9BUF5 | 4/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL385535 | 1.00 | ENPP2 (0.52) | ENPP2TRPV4MEN1KMT2AERN1 | |
| Ethylene Glycol SCHEMBL28089477 | 0.93 | ENPP2 (0.46) | ENPP2TRPV4MEN1KMT2AERN1 | |
| SCHEMBL19204646 | 0.88 | TRPV4 (0.44) | ENPP2TRPV4MEN1KMT2AERN1 | |
| SCHEMBL322537 | 0.83 | ENPP2 (0.52) | ENPP2TRPV4MEN1KMT2AERN1 | |
| SCHEMBL25308686 | 0.80 | ENPP2 (0.41) | ENPP2TTRSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL20704942 | 0.80 | ENPP2 (0.44) | ENPP2TRPV4MEN1KMT2ASLC6A2 | |
| SCHEMBL29447064 | 0.80 | ENPP2 (0.44) | ENPP2TRPV4MEN1KMT2ASLC6A2 | |
| SCHEMBL29952519 | 0.79 | TSHR (0.49) | ENPP2MEN1KMT2ASLC6A2SLC6A4 | |
| SCHEMBL1686371 | 0.79 | TSHR (0.49) | ENPP2MEN1KMT2ASLC6A2SLC6A4 | |
| SCHEMBL15330282 | 0.78 | PLAU (0.44) | ENPP2LMNAFLT1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025215450-A1 | THIAZOLE COMPOUNDS AS SODIUM CHANNEL BLOCKERS | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2025-10-16 | — | — | WO | disclosed |
| EP-4609865-A2 | NLRP3 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2025-09-03 | — | — | EP | disclosed |
| EP-4337652-B1 | NLRP3 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2025-04-09 | — | — | EP | disclosed |
| EP-4519265-A1 | IRREVERSIBLE MUTEGFR INHIBITORS | Bayer Aktiengesellschaft (DE) | 2025-03-12 | — | — | EP | disclosed |
| EP-4504733-A1 | FUSED PYRIDAZINE DERIVATIVES AS NLRP3 INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2025-02-12 | — | — | EP | disclosed |
| WO-2024191248-A1 | COMPOUND, ORGANIC LIGHT-EMITTING DEVICE, AND COMPOSITION FOR ORGANIC LIGHT-EMITTING DEVICE | 엘티소재주식회사 | 2024-09-19 | — | — | WO | disclosed |
| US-20240208928-A1 | NOVEL COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2024-06-27 | — | — | US | disclosed |
| WO-2024006776-A1 | ESTROGEN RECEPTOR ALPHA DEGRADERS AND MEDICAL USE THEREOF | RELAY THERAPEUTICS, INC. (US) | 2024-01-04 | — | — | WO | disclosed |
| WO-2023213882-A1 | IRREVERSIBLE MUTEGFR INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2023-11-09 | — | — | WO | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| WO-2022203323-A1 | SUBSTANCE FOR FORMING NUCLEATION INHIBITION AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING SAME | 주식회사 랩토 | 2022-09-29 | — | — | WO | disclosed |
| WO-2022119174-A1 | DIBENZO 5-MEMBERED CYCLIC COMPOUND, AND ORGANIC ELECTROLUMINESCENCE DEVICE COMPRISING SAME | 주식회사 랩토 | 2022-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240208928-A1 | NOVEL COMPOUNDS | RB1, RPS4X, RPS4Y1 | ENPP2 1445/4885TRPV4 3354/4885MEN1 589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.